Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization

FcRn Antibody Fragment Submitted To US FDA In January

Feb 05 2021

• By Mandy Jackson

Finance Watch

Related Content

Keeping Track: Keytruda Adds TNBC Claim; Finerenone, Brincidofovir, HTX-011 Submitted; CRL For Supernus’ ADHD Drug

Nov 14 2020

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

Jan 18 2021

Deal Watch: Roche Partners With Dyno On AAV-Delivered Gene Therapies

Oct 14 2020

CytomX’s Probody T-Cell Platform Produces Astellas Pact

Mar 25 2020

Belgium's Argenx Advances On More Positive Efgartigimod Data

Oct 05 2020

Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019

Feb 25 2019

IPO Update: New Offerings Outperform As September Ends With Biopharma Trifecta

Sep 29 2017

CureVac Launches IPO, Adds To Big 2020 Cash Haul

Aug 14 2020

Finance Watch: Intrexon Reorganizes, Raises Cash And Becomes Precigen

Jan 03 2020

Rhythm May Have Data To Add Indication To Imcivree’s Label

Dec 22 2020

Editas And Allergan Launch World’s First In Vivo CRISPR Trial

Mar 05 2020

Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds

May 20 2017

First Of Its Kind: Beam Seeks To Erase-And-Replace Single Letters In DNA's Alphabet

May 15 2018

ESMO: Daiichi's HER3-Targeting ADC Shows Promise, Particularly In Resistant Tumors

Sep 22 2020

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

Sep 18 2020

Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold

Sep 28 2020

Impressive Clinical Results For Argenx’s Oncology Candidate Seal The Deal for Janssen

Dec 03 2018

Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta

Jul 20 2018

Beam And Verve Benefit From Buzz Around Base-Editing Therapies

Jan 20 2021

Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor

Jan 13 2021

CureVac Enlists Bayer To Secure Place Among COVID-19 Vaccines ‘Second Wave’

Jan 07 2021

Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio

May 27 2020

Finance Watch: Biopharma Stocks See Big Post-IPO Jumps

Feb 12 2020

Deal Watch: Bayer Teams With Nuvisan On Berlin-Based Small Molecule Research Group

Feb 14 2020

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Feb 21 2020

Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump

Feb 03 2020

Related Companies

argenx N.V.

Zai Lab Ltd.

Janssen Pharmaceutical Cos.

BridgeBio Pharma, Inc.

Eidos Therapeutics, Inc.

CureVac NV

Bayer AG

Revolution Medicines, Inc.

Beam Therapeutics Inc.

Editas Medicine

Allergan plc

Arcus Biosciences, Inc.

Gilead Sciences, Inc.

Arcutis Biotherapeutics, Inc.

Inovio Pharmaceuticals, Inc.

Dyne Therapeutics

Rhythm Pharmaceuticals, Inc.

TCR² Therapeutics Inc.

Precigen, Inc.

Krystal Biotech, Inc.

Merus N.V.

Chimerix, Inc.

Oncoceutics, Inc.

CytomX Therapeutics, Inc.

Additional Topics

Financing StartUps and SMEs Companies Business Strategies Commercial BioPharmaceutical

More from Financing

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.